KEY DETAILS
cnbctv18.com reports that Dr Reddy's also plans to launch semaglutide in nine additional markets beyond Canada.
Koreatimes.co.kr reports that 10.3 percent of surveyed Korean adults said they used or were prescribed GLP-1 obesity drugs in the past year.
Santafenewmexican.com reports that unapproved products labeled 'Reta,' 'GLP-3,' 'research peptides' or compounded retatrutide are easy to find online.
Moneycontrol.com reports that Dr Reddy's plans the Canada relaunch after resolving manufacturing issues that forced a temporary withdrawal from the market.
Economictimes.indiatimes.com reports that Dr Reddy's aims to sell millions of pens for semaglutide with a focus on international markets.
CNBC-TV18 reports that Dr Reddy's is preparing to relaunch semaglutide in Canada, with the launch expected by November. The company also plans to enter nine additional markets, according to CNBC-TV18. And the Korea Times reports that 10.3 percent of surveyed Korean adults said they used or were prescribed GLP-1 obesity drugs in the past year.
CNBC-TV18 reports that Dr Reddy's plans to launch semaglutide in nine markets beyond Canada, broadening its international footprint. That is a lot of new ground to cover at once. The outlet also reports that Dr Reddy's posted revenues of ₹8,671 crore and net profit of ₹913 crore for the July-September quarter, with net interest margins at 20.6 percent. Those figures give some sense of the resources behind the expansion.
Interest in these drugs is not confined to one country's drugstore shelves. The Korea Times reports that 10.3 percent of the 2,000 adults surveyed for the 2026 Korea Wellness Report said they used or were prescribed GLP-1 obesity drugs in the past year. The outlet also reports that usage varied by generation, with Generation Z at 16.5 percent, millennials at 14.2 percent, Generation X at 7.7 percent and baby boomers at 2.9 percent. The Korea Times reports that 33.9 percent of respondents said they would use obesity drugs if circumstances allowed, rising to 39.7 percent among Generation Z, who cited appearance and body shape management as their top reason.
Not everyone is waiting for an approved prescription, though. Santa Fe New Mexican reports that products labeled 'Reta,' 'GLP-3,' 'research peptides' or compounded retatrutide are easy to find online. The outlet reports that newer medications like retatrutide act on multiple pathways in the body, making them more complex. According to Santa Fe New Mexican, questions remain about retatrutide's long-term safety, its effects on lean tissue, how to maintain results and who is most likely to benefit or be harmed. The outlet states that no promise of faster weight loss is worth the risk of injecting an unapproved drug.
Back on the manufacturing side, there is an explanation for why Canada needed a pause at all. Moneycontrol reports that the Canada relaunch follows manufacturing issues that had forced a temporary withdrawal from the market there. The outlet also reports that CFO MV Narasimham pointed to a December target action date from the USFDA for an abatacept intravenous formulation, with the company expecting a significant first-mover advantage. Moneycontrol reports that Dr Reddy's CDMO arm, Aurigene Pharmaceutical Services, crossed $100 million in revenue over the last 12 months, as part of what Narasimham described as a fresh growth cycle built on the semaglutide relaunch, a biosimilars pipeline and an expanding India franchise.
The ambitions attached to that relaunch are not small. The Economic Times reports that Dr Reddy's aims to sell millions of pens for semaglutide, with a focus on international markets. The outlet also reports that a relaunch of generic semaglutide, alongside the US launch of an abatacept biosimilar, is anticipated for future growth. According to the Economic Times, generic semaglutide and biosimilars are central to the company's growth strategy going forward.
You can find the full details on Dr Reddy's Canada plans at CNBC-TV18 and Moneycontrol, the Korea Wellness Report findings at the Korea Times, the online retatrutide warning at the Santa Fe New Mexican, and the growth strategy breakdown at the Economic Times.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.